GT Biopharma Inc (GTBP) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
GT Biopharma Inc stock (GTBP) is currently trading at $0.47. GT Biopharma Inc PS ratio (Price-to-Sales) is 204.96. Analyst consensus price target for GTBP is $3.00. WallStSmart rates GTBP as Sell.
- GTBP PE ratio analysis and historical PE chart
- GTBP PS ratio (Price-to-Sales) history and trend
- GTBP intrinsic value — DCF, Graham Number, EPV models
- GTBP stock price prediction 2025 2026 2027 2028 2029 2030
- GTBP fair value vs current price
- GTBP insider transactions and insider buying
- Is GTBP undervalued or overvalued?
- GT Biopharma Inc financial analysis — revenue, earnings, cash flow
- GTBP Piotroski F-Score and Altman Z-Score
- GTBP analyst price target and Smart Rating
GT Biopharma Inc
📊 No data available
Try selecting a different time range
Smart Analysis
GT Biopharma Inc (GTBP) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
GT Biopharma Inc (GTBP) Key Strengths (1)
Good growth relative to its price
Supporting Valuation Data
GT Biopharma Inc (GTBP) Areas to Watch (5)
Company is destroying shareholder value
Very expensive at 205.0x annual revenue
Very low institutional interest at 4.33%
Micro-cap company with very limited liquidity and high volatility
Fairly priced relative to book value
Supporting Valuation Data
GT Biopharma Inc (GTBP) Detailed Analysis Report
Overall Assessment
This company scores 22/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 1 register as strengths (avg 8.0/10) while 5 fall into concern territory (avg 2.6/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on PEG Ratio. Valuation metrics including PEG Ratio (1.05) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Price/Sales, Institutional Own.. Some valuation metrics including Price/Sales (204.96), Price/Book (2.51) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -1377.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -1377.00% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Sales are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
GTBP Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
GTBP's Price-to-Sales ratio of 204.96x sits near its historical average of 204.96x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 0% below its historical high of 204.96x set in Mar 2026, and 0% above its historical low of 204.96x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for GT Biopharma Inc (GTBP) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
GT Biopharma Inc operates as a stable business with moderate growth and solid fundamentals. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Free cash flow is -4M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact GT Biopharma Inc.
Bottom Line
GT Biopharma Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(0 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 8:27:08 AM
About GT Biopharma Inc(GTBP)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
GT Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its patented immune-enhancer cell fusion protein Tri-specific Killer Engager (TriKE) technology platform. The company is headquartered in Beverly Hills, California.